Association of an Automated Breast Arterial Calcification Score with Cardiovascular

Outcomes and Mortality

*Quan M. Bui, MD[1]; *Tara Shrout Allen, MD, MSc[2];Richard Mantey, MS[3]; Gregory M.

Petersen, MD[1]; Junhao Wang, MS[3]; Nitesh Nerlekar, MBBS, MPH, PhD[4]; Mohammad

Eghtedari, MD, PhD[5]; Lori B. Daniels, MD, MAS[1]

[1] Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA

[2] Division of Preventive Medicine, University of California San Diego, La Jolla, CA

[3] Research Team, CureMetrix, Inc., La Jolla, CA

[4] Baker Heart and Diabetes Institute, Melbourne, Australia; Victorian Heart Institute & Monash

Health Heart, Monash University, Clayton, Australia

[5] Department of Radiology, University of California San Diego, La Jolla, CA

* Equal contributions and co-first authors

Address for Correspondence:

Quan M. Bui, MD

University of California, San Diego, Division of Cardiovascular Medicine

9452 Medical Center Drive #7411

La Jolla, CA 92037-7411

Phone: (858) 246-1326

Fax: (858) 657-1828

Email: q3bui@health.ucsd.edu

Keywords: breast arterial calcification, cardiovascular outcomes, artificial intelligence,

personalized risk stratification, preventive medicine

ABSTRACT

Background

Breast arterial calcification (BAC), visible on mammograms, has emerged as a biomarker of

cardiovascular disease (CVD) in women. Barriers to clinical implementation of BAC include

limited studies with clinical outcomes and lack of quantification tools.

Methods

This single-center, retrospective study included women with a screening digital mammogram

from 2008-2016. BAC was quantified using an automated, artificial intelligence (AI)-generated

Bradley score, as a binary (Bradley score ≥5) and continuous variable. Clinical outcomes were

determined via electronic medical records. Regression analyses were used to evaluate the

association between BAC and outcomes of mortality and a composite of acute myocardial

infarction, heart failure, stroke, and mortality. Models were adjusted for age, race, diabetes,

smoking status, blood pressure, cholesterol, and history of CVD and chronic kidney disease.

Results

A total of 18,092 women were included with a mean age 56.8±11.0 years. Prevalence of

comorbidities included diabetes (13%), hypertension (36%), hyperlipidemia (40%) and smoking

(5%). BAC was present in 4,223 (23%). Over a median follow-up of 6 years, death occurred in

7.8% women with and 2.3% women without BAC. The composite outcome occurred in 12.4% of

women with and 4.3% of women without BAC. Compared to those without, women with BAC

had adjusted hazard ratios (aHR) of 1.49 (95% CI 1.33-1.67) for mortality and 1.56 (1.41-1.72)

for the composite endpoint, after accounting for traditional risk factors. With a continuous BAC

score, each 10-point increase was associated with higher risk of mortality (1.08 [1.06-1.11]) and

the composite endpoint (1.08 [1.06-1.10]). BAC was especially predictive of future events

among younger women.

Conclusion

BAC is significantly and independently associated with mortality and incident CVD, especially

among younger women. Measuring BAC using an AI algorithm is feasible and clinically

relevant. Further studies are needed to confirm these findings and to evaluate whether

interventions guided by BAC improve outcomes.

CLINICAL PERSPECTIVE

What is new?

• Breast arterial calcification (BAC) on mammograms can be reliably quantified using a

novel software based on an artificial intelligence (AI) algorithm.

• BAC is independently associated with an increased risk of all-cause mortality and

cardiovascular outcomes. These associations held true when looking at BAC as presence,

score quartile, and as a continuous value as well as after accounting for traditional

cardiovascular risk factors.

• In stratification analysis, BAC was most predictive of all-cause mortality and

cardiovascular outcomes among younger women (age 40-59 years), but still

independently predictive in women aged 60-74 years.

What are the clinical implications?

• Our data provide support for the inclusion of BAC findings on mammogram reports.

• Automated quantification tools and reporting methods of BAC will be critical to

engagement of radiologists and implementation of reporting.

• While additional studies are needed to determine the appropriate clinical response, the

presence of BAC should at the minimum stimulate patient-provider conversations on

lifestyle changes to mitigate cardiovascular risk, especially among younger women.

INTRODUCTION

Cardiovascular disease (CVD) remains the leading cause of death in women despite significant advances in cardiovascular diagnostics and treatments.[1] Delays in diagnosis and treatment, as well as under-treatment, contribute to morbidity and mortality.[2] This problem is further exacerbated by under-representation of women in cardiovascular clinical trials and lack of sex-specific CVD screening tools.[3] Methods to broadly screen women that are efficient and effective are sorely needed.

Breast arterial calcification (BAC), an incidental finding on mammograms, has emerged as a sex-specific biomarker for atherosclerotic cardiovascular disease (ASCVD) that offers the potential for personalized risk stratification.[4] Gleaning information from an imaging study beyond its original intent is not new; analogous to BAC on mammography is coronary artery calcifications seen on chest computed tomography obtained for non-cardiac purposes.[5] BAC has tremendous appeal because it is non-invasive, comes at no additional cost or radiation, and the majority of women over the age of 40 years already undergo annual screening mammography for breast cancer.[6]

Multiple studies have found significant associations between the presence of BAC and prevalent CVD.[4] It is postulated that BAC represents lifetime exposure to risk factors related to arterial stiffening, which increases the risk of CVD through both coronary and non-coronary mechanisms (i.e. heart failure and stroke).[7] However, routine clinical use of BAC has not been adopted due to a lack of outcomes studies as well as technological challenges in measuring and reporting BAC.[4] The purpose of this study was to evaluate the association of BAC with CVD

risk factors and hard clinical outcomes as well as to validate an automated, artificial intelligence

(AI) algorithm for BAC quantification.

METHODS

Study Population

This single-center retrospective study included women between the ages of 40 and 90 years who

underwent screening digital mammography between 2008 to 2016 at University of California

(UC) San Diego Health. For each subject, only the index mammogram was analyzed. All

protocols were approved by the Institutional Review Board of UC San Diego Health (IRB

#170154).

Evaluation of BAC

BAC was quantified using a validated, proprietary software (cmAngio™, CureMetrix) based on

a deep neural, AI network and previously trained using over 21,000 2D full-field digital

mammograms (FFDM) obtained from multiple sites in Australia, Brazil, and the United States

(not including UC San Diego Health).[8] For the present study, four FFDM images from each

participant were used. The software cmAngio™ assesses screening mammography images and

feeds them through the deep learning model to identify regions of interest within the breast.

These regions correspond to areas that the algorithm suspects to have a high probability of BAC.

From these identified regions, local and global imaging features such as density, contrast, and

other physical dimensions are combined to determine the severity of BAC. This process is

applied to each of the four standard screening mammography images. Following these

calculations, each image is assigned a score between 0-100 corresponding to the severity of the

BAC finding(s), with 0 representing no BAC and 100 representing a level of BAC within the

highest percentile. To balance the algorithm's false positive and false negative rate, all image-

level scores less than 5 are floored to 0. The patient level score (or Bradley Score) is the mean of

the threshold image-level scores across all 4 views. In this study, BAC was evaluated both as a

binary (presence vs absence), and as a continuous variable (Bradley Score 0-100), as well as by

quartiles (1st to 4th). BAC presence was defined as a mean Bradley Score $\geq$ 5. Scores were

distributed by severity into the following quartiles: 1st Quartile [Score 1-25], 2nd Quartile [Score

26-50], 3rd Quartile [Score 51-75], and 4th Quartile [Score 76-100].

Clinical Data and Outcomes

The primary outcome was all-cause mortality, which is thereafter referenced as mortality.

Secondary outcomes included acute myocardial infarction (MI), heart failure, stroke, and a

cardiovascular composite outcome (MI, heart failure, stroke, and mortality). Those with baseline

MI, heart failure, and/or stroke were excluded from the relevant outcome and composite

analyses. Outcomes were collected via electronic medical records (EMR) using International

Classification of Disease ICD-10 diagnoses until death or the censoring date of December 31st,

2020. Additional clinical data including baseline characteristics, medical history, vital signs and

labs were collected using the EMR.

Analyses and Statistical Methods

Continuous variables were reported either as mean with standard deviation or as median with

interquartile range as appropriate based on normality of distribution assessed by Shapiro-Wilk

test. Categorical variables were expressed as counts with percentages. Variables were compared

using the unpaired Student t-test, Mann-Whitney test, and Fisher exact test, as appropriate.

Kaplan-Meier curves were plotted, and Cox Proportional Hazards regression analyses were used

to determine associations between BAC (as a binary and continuous variable) and clinical

outcomes, sequentially controlling for age, race/ethnicity, smoking status, systolic blood pressure

(SBP), diastolic blood pressure (DBP), total cholesterol, low density lipoprotein (LDL)

cholesterol, diabetes mellitus, and history of CVD or CKD, as measured at the time of FFDM.

Age was continuous and measured in years. Smoking status was categorical and defined as

current, former, never, or unknown. SBP and DBP were continuous and measured in mmHg.

Total cholesterol and LDL cholesterol were continuous and measured in mg/dL. Diabetes

mellitus and CKD were defined as per the relevant ICD code. CVD was defined as an ICD code

for any of the following: atherosclerotic cardiovascular disease (ASCVD), MI, acute ischemic

heart disease, cerebrovascular disease, coronary artery disease (CAD), heart failure, or stroke.

For those without covariate data from the time of FFDM, imputation was performed to account

for these missing data. Data were imputed by training a nearest neighbor multiple-imputation

model in Python to predict missing variables using the 10 nearest neighbors based on the

collected diagnosis codes, age, ethnicity, smoking status, blood pressure (systolic and diastolic),

and cholesterol (total and LDL).

Forest plots were created to assess the association between BAC and outcomes, stratified by

subgroups of baseline characteristics. Tails represent 95% confidence intervals [CIs]. All

reported p-values were two-sided with a value of <0.05 considered statistically significant.

Statistical analyses and figures were completed using Python 3.11.5 with packages including

Pandas 2.1.0 and SciPy 1.11.2.

RESULTS

Study Population

A total of 21,438 screening mammograms were obtained between 2008 and 2016. Of these,

1,546 mammograms were excluded for age and 1,800 mammograms were excluded for not being

the index study. Therefore, 18,092 women with index mammograms were included in the study

(**Figure 1**).

194
195

208   **Figure 1.** **Participant Flow Diagram**
209   After exclusions for age and non-index mammograms, there were 18,092 unique women with
210   index mammograms included in this study.
211

212   Among the 18,092 women included, the mean age was 56.8 ±11.0 years ; prevalent CVD risk

213   factors included diabetes (13%), hypertension (36%), and hyperlipidemia (40%) (**Table 1**).

214   BAC was present in 4,223 (23%). BAC was more prevalent among women who were older,

215   Black or Hispanic, diabetic, hypertensive, with a history of CVD or CKD, and among those

taking cardiac medications. BAC was less prevalent in current smokers. Among those with BAC,

the median Bradley score was 15 (IQR 4, 50). Scores were distributed by severity into the

following quartiles: 1st Quartile [Score 1-25], n=2552 (60.4%); 2nd Quartile [Score 26-50], n=643

(15.2%); 3rd Quartile [Score 51-75], n=509 (12.1%); and 4th Quartile [Score 76-100], n=519

(12.3%). Those with a higher Bradley Score were more likely to be older, have diabetes,

hypertension, hyperlipidemia, history of CVD and CKD, and take statin and antihypertensive

medications. (**Supplementary Table 1**).

Table 1. Baseline Participant Characteristics by Presence of Breast Arterial Calcification

Baseline Characteristics	Total (n=18,092)	BAC Present (n=4,223; 23%)	BAC Absent (n=13,869; 77%)	p
Age, mean years (SD)	56.8 (11.4)	65.2 (11.6)	54.2 (10.0)	<0.001
Race/Ethnicity				
Caucasian, No. (%)	11,319 (62.6)	2,617 (62.0)	8,702 (62.7)	0.38
Black/African American, No. (%)	907 (5.0)	241 (5.7)	666 (4.8)	0.02
Hispanic/Latino, No. (%)	1,694 (9.4)	455 (10.8)	1,239 (8.9)	<0.001
Asian/Pacific Islander, No. (%)	2,321 (12.8)	496 (11.8)	1,825 (13.2)	0.02
Other, No. (%)	1,851 (10.2)	414 (9.8)	1,437 (10.4)	0.31
Diabetes, No, (%)	2,267 (12.5)	730 (17.3)	1,537 (11.1)	<0.001
Hypertension, No. (%)	6,529 (36.1)	2,179 (51.6)	4,350 (31.4)	<0.001
Hyperlipidemia, No. (%)	7,256 (40.1)	2,071 (49.0)	5,185 (37.4)	<0.001
History of CVD, No. (%)	874 (4.8)	424 (10.0)	450 (3.2)	<0.001
History of CKD, No. (%)	802 (4.4)	358 (8.48)	444 (3.2)	<0.001
Current smoking, No. (%)	834 (4.6)	134 (3.17)	700 (5.1)	<0.001
Never smokers, No. (%)	9,245 (51.1)	2,046 (48.5)	7,199 (52.6)	<0.001
SBP, mmHg (IQR)	123 (21)	128 (20)	122 (20)	<0.001
Total cholesterol, mg/dL (IQR)	198 (52)	194 (53)	199 (51)	<0.001
Statin use, No. (%)	3,947 (21.8)	1,430 (33.9)	2,517 (18.1)	<0.001
Antihypertensive use, No. (%)	3,498 (19.3)	1,313 (31.1)	2,185 (15.8)	<0.001
BAC, breast arterial calcification; SD, standard deviation; No, number; IQR, interquartile range; CKD, chronic kidney disease; CVD, cardiovascular disease; SBP, systolic blood pressure.				

Supplementary Table 1. Baseline Participant Characteristics by Bradley Score Quartiles

Baseline Characteristics	1st Quartile [Score 1-25], n=2,552 (60.4%)	2nd Quartile [Score 26-50], n=643 (15.2%)	3rd Quartile [Score 51-75], n=509 (12.1%)	4th Quartile [Score 76-100], n=519 (12.3%)	p
Age, mean years (SD)	61.6 (11.3)	67.8 (9.9)	71.2 (9.4)	73.6 (9.2)	<0.001
Race/Ethnicity					
Caucasian, No. (%)	1651 (64.7)	412 (64.1)	316 (62)	238 (45.9)	<0.001
Black/African American, No. (%)	129 (5.1)	37 (5.8)	30 (5.9)	45 (8.7)	0.01
Hispanic/Latino, No. (%)	226 (8.9)	71 (11.0)	59 (11.6)	99 (19.1)	<0.001
Asian/Pacific Islander, No. (%)	292 (11.4)	72 (11.2)	53 (10.4)	79 (15.2)	0.06
Other, No. (%)	254 (10.0)	51 (7.9)	51 (10.0)	58 (11.2)	0.29
Diabetes, No, (%)	147 (5.8)	63 (9.8)	48 (9.4)	92 (17.7)	<0.001
Hypertension, No. (%)	776 (30.4)	273 (42.5)	266 (52.3)	293 (56.5)	<0.001
Hyperlipidemia, No. (%)	690 (27.0)	234 (36.4)	213 (41.9)	228 (43.9)	<0.001
History of CVD, No. (%)	177 (6.9)	62 (9.6)	67 (13.2)	118 (22.7)	<0.001
History of CKD, No. (%)	56 (2.2)	23 (3.6)	19 (3.7)	36 (6.9)	<0.001
Current smoking, No. (%)	96 (3.8)	17 (2.6)	7 (1.4)	14 (2.7)	0.03
Never smokers, No. (%)	1284 (50.3)	279 (43.4)	237 (46.6)	246 (47.4)	0.01
SBP, mmHg (IQR)	126 (19.0)	130 (16.0)	132 (19.0)	132 (18.0)	<0.001
Total cholesterol, mg/dL (IQR)	204 (26.0)	203 (29.5)	203 (28.6)	197 (28.4)	<0.001
Statin use, No. (%)	714 (28.0)	253 (39.3)	214 (42.0)	249 (48.0)	<0.001
Antihypertensive use, No. (%)	618 (24.2)	235 (36.6)	207 (40.7)	253 (48.7)	<0.001

BAC, breast arterial calcification; SD, standard deviation; No, number; CKD, chronic kidney disease; CVD, cardiovascular disease; IQR, interquartile range; SBP, systolic blood pressure.

Clinical Outcomes

Over a median follow-up for mortality of 6 years [range, 6 months – 12 years], there were 329 deaths in those with BAC (7.8%) and 313 deaths in those without BAC (2.3%) (**Table 2).** Over a median follow-up for the CVD composite outcome of 4.4 years [range, 6 months – 12 years], there were 500 events (12.4%) in those with BAC and 582 events in those without BAC (4.3%). Kaplan-Meier Plots for mortality and the composite outcome are shown in **Figure 2**, which demonstrate a significantly increased risk of outcomes in those with BAC (p<0.001 for each).

237   Kaplan-Meier Plots for individual MI, Stroke, and HF outcomes are shown in **Supplementary**

238   **Figure 1,** which also demonstrate significantly increased risk in those with BAC (p<0.001 for

239   each outcome).

240
241   **Table 2. Clinical Outcomes by Breast Arterial Calcification Presence**
242

Incident Clinical Outcomes	Total (n=18,092)		BAC Present (n=4,223)		BAC Absent (n=13,869)		*p*
Myocardial infarction, No. (%)	18,051	83 (0.5%)	4,204	36 (0.9%)	13,847	47 (0.3%)	<0.001
Heart failure, No. (%)	17,911	298 (1.7%)	4,119	154 (3.7%)	13,792	144 (1.0%)	<0.001
Stroke, No. (%)	17,914	259 (1.5%)	4,138	110 (2.7%)	13,776	149 (1.1%)	<0.001
Mortality, No. (%)	18,092	642 (3.6%)	4,223	329 (7.8%)	13,869	313 (2.3%)	<0.001
Composite Outcome*, No. (%)	17,720	1,082 (6.1%)	4,031	500 (12.4%)	13,689	582 (4.3%)	<0.001
BAC, breast arterial calcification; No, number. *The cardiovascular composite outcome included acute myocardial infarction, heart failure, stroke, and mortality.							

244
245

246
247

Figure 2. Kaplan-Meier Plots for Mortality and Composite Outcome by Breast Arterial Calcification Presence
Risk for (**A**) mortality, and (**B**) the cardiovascular composite outcome significantly varied by the presence of breast arterial
calcification (p<0.001 for each). The composite outcome included acute myocardial infarction, heart failure, stroke, and mortality.
BAC indicates breast arterial calcification; BAC+, presence of BAC and BAC-, absence of BAC.

Supplementary Figure 1. **Kaplan-Meier Plots for Acute Myocardial Infarction, Heart Failure, and Stroke by Presence of Breast Arterial Calcification** Risk for (**A**) acute myocardial infarction, (**B**) heart failure, and (**C**) Stroke each significantly varied by the presence of breast arterial calcification (p<0.001) when comparing the unadjusted Kaplan-Meier Curves. BAC indicates breast arterial calcification; BAC+, presence of BAC and BAC-, absence of BAC.

On multivariable analysis, women with BAC had a higher risk of mortality (aHR 1.49 [95% CI

1.33-1.68]) and the composite outcome (aHR 1.57 [95% CI 1.42-1.74]), compared to those

without BAC, in fully adjusted models (**Table 3**). With BAC quantified by quartiles, there was a

graded increased risk for mortality and the composite outcome with increasing quartile, even

after adjustment for cardiovascular risk factors (**Table 4**). When analyzed as a continuous

Bradley score, each 10-point increase in BAC was significantly and independently associated

with higher risk for adverse clinical outcomes: mortality (aHR 1.08 [95% CI 1.06, 1.11], p <

0.001) and composite outcome (aHR 1.08 [95% CI 1.06, 1.10], p < 0.001) (**Table 4**). Similar

associations with BAC were seen for heart failure and stroke, though results for myocardial

infarction (n=83 events) did not reach statistical significance. (**Supplementary Tables 2 and 3**).

273
274 **Table 3.** **Association of Breast Arterial Calcification and Mortality and Composite Outcome**
275

	Mortality (n=642/18,092) HR (95% CI)	p	Composite Outcome* (n=1,082/17,720) HR (95% CI)	p
Among all participants				
Model 1	**1.70 (1.52, 1.90)**	**<0.001**	**1.92 (1.74, 2.11)**	**<0.001**
Model 2	**1.58 (1.41, 1.77)**	**<0.001**	**1.67 (1.51, 1.84)**	**<0.001**
Model 3	**1.49 (1.33, 1.68)**	**<0.001**	**1.57 (1.42, 1.74)**	**<0.001**

*Composite Outcome: acute myocardial infarction, heart failure, stroke, and mortality. Model 1: unadjusted. Model 2: adjusted for age and race/ethnicity. Model 3: adjusted for age, race/ethnicity, systolic blood pressure, diastolic blood pressure, diabetes, total cholesterol, low-density lipoprotein cholesterol, history of cardiovascular disease, history of chronic kidney disease, and smoking status. HR, hazard ratio; CI, confidence interval.

276
277
278 **Table 4.** **Association of Bradley Score Quartiles and Mortality and Composite Outcome**
279

	Mortality (n=642/18,092) HR (95% CI)	p	Composite Outcome* (n=1,082/17,720) HR (95% CI)	p
BAC negative, n=13,869	*Referent*	--	*Referent*	--
Per 10-point Bradley Score Increase	**1.08 (1.06, 1.11)**	**<0.001**	**1.08 (1.06, 1.10)**	**<0.001**
1st Quartile [Score 1-25], n=2552	**1.22 (1.06, 1.41)**	**0.006**	**1.26 (1.11, 1.43)**	**<0.001**
2nd Quartile [Score 26-50], n=643	**1.44 (1.13, 1.85)**	**0.004**	**1.74 (1.42, 2.13)**	**<0.001**
3rd Quartile [Score 51-75], n=509	**1.69 (1.33, 2.14)**	**<0.001**	**1.83 (1.49, 2.25)**	**<0.001**
4th Quartile [Score 76-100], n=519	**2.27 (1.81, 2.85)**	**<0.001**	**2.30 (1.88, 2.82)**	**<0.001**

*Composite Outcome: acute myocardial infarction, heart failure, stroke, and mortality. All data from the multivariable-adjusted model (Model 3), which adjusted for age, race/ethnicity, systolic blood pressure, diastolic blood pressure, diabetes, total cholesterol, low-density lipoprotein cholesterol, history of cardiovascular disease, history of chronic kidney disease, and smoking status. HR, hazard ratio; CI, confidence interval.

280
281 **Supplementary Table 2.** Association of Breast Arterial Calcification Presence and
282 Cardiovascular Outcomes
283

	Heart Failure (n=298/17,911) HR (95% CI)	p	Myocardial Infarction (n=83/18,051) HR (95% CI)	p	Stroke (n=259/17,914) HR (95% CI)	p
Among all participants						
Model 1	**1.51 (1.33, 1.73)**	**<0.001**	1.11 (0.96, 1.28)	0.184	**1.29 (1.13, 1.48)**	**<0.001**
Model 2	**1.46 (1.28, 1.66)**	**<0.001**	1.10 (0.95, 1.28)	0.200	**1.25 (1.09, 1.43)**	**0.001**
Model 3	**1.41 (1.24, 1.61)**	**<0.001**	1.10 (0.95, 1.27)	0.214	**1.22 (1.07, 1.40)**	**0.003**

*Composite Outcome: acute myocardial infarction, heart failure, stroke, and mortality. Model 1: unadjusted. Model 2: adjusted for age and race/ethnicity. Model 3: adjusted for age, race/ethnicity, systolic blood pressure, diastolic blood pressure, diabetes, total cholesterol, low-density lipoprotein cholesterol, history of cardiovascular disease, history of chronic kidney disease, and smoking status. HR, hazard ratio; CI, confidence interval.

284
285
286 **Supplementary Table 3.** Association of The Bradley Score and Cardiovascular Outcomes
287

	Heart Failure (n=298/17,911) HR (95% CI)	p	Myocardial Infarction (n=83/18,051) HR (95% CI)	p	Stroke (n=259/17,914) HR (95% CI)	p
BAC negative, n=13,869	*Referent*	--	*Referent*	--	*Referent*	--
1st Quartile [Score 1-25], n=2552	**1.17 (1.00, 1.38)**	**0.049**	1.03 (0.86, 1.23)	0.767	1.06 (0.90, 1.25)	0.501
2nd Quartile [Score 26-50], n=643	**1.38 (1.03, 1.85)**	**0.029**	1.23 (0.88, 1.71)	0.232	**1.35 (1.00, 1.82)**	**0.048**
3rd Quartile [Score 51-75], n=509	**2.03 (1.49, 2.76)**	**<0.001**	1.14 (0.79, 1.66)	0.485	1.19 (0.85, 1.67)	0.322
4th Quartile [Score 76-100], n=519	**1.70 (1.23, 2.35)**	**0.001**	1.12 (0.77, 1.63)	0.563	**1.76 (1.27, 2.44)**	**<0.001**

*Composite Outcome: acute myocardial infarction, heart failure, stroke, and mortality. All data from the multivariable-adjusted model (Model 3), which adjusted for age, race/ethnicity, systolic blood pressure, diastolic blood pressure, diabetes, total cholesterol, low-density lipoprotein cholesterol, history of cardiovascular disease, history of chronic kidney disease, and smoking status. HR, hazard ratio; CI, confidence interval.

Breast Arterial Calcification and Clinical Outcomes Among Subgroups

BAC prediction for mortality and the composite cardiovascular outcome significantly varied by

age, SBP, total cholesterol, LDL cholesterol, smoking, and diabetes (p-interaction terms <0.001

for each) (**Supplementary Table 4**). Additionally, prediction significantly varied by history of

CVD for mortality (p-interaction term <0.001) and the composite outcome (p-interaction term

0.009). While prediction also significantly varied by history of CKD for mortality (p-interaction

term 0.004), it did not for the composite outcome (p-interaction term 0.16). Kaplan-Meier Plots

for mortality and the composite outcome stratified by age groups (**Figure 3**) demonstrate a

significant separation of curves for women aged 40-59 and 60-74 years of age (p<0.001), but not

for those aged 75-90 years (morality, p=0.10; composite, p=0.05). Forest plots demonstrating

adjusted hazard ratios (aHR) for outcomes by stratification of baseline characteristics are shown

in **Figure 4**. When stratified by age groups, and after accounting for traditional risk factors, those

in the youngest age group of 40-59 years had the highest residual risk associated with BAC

(mortality: aHR 1.51, 95% CI 1.22-1.87; composite outcome: aHR 1.52, 95% CI 1.25-1.85).

There remained significantly increased risk associated with BAC beyond traditional risk factors

for women aged 60-74 years (mortality: aHR 1.26, 95% CI 1.06-1.50; composite outcome: aHR

1.36, 95% CI 1.18-1.58), but not among those aged 75 to 90 years (mortality: aHR 1.19 , 95%

CI 0.91-1.54; composite outcome: aHR 1.23, 95% CI 0.98-1.55). When stratified by several

other baseline characteristics, including systolic blood pressure and diabetes, the association

between BAC and future cardiovascular events remained robust, even after accounting for

traditional risk factors (**Figure 4**).

 Figure 3. Association of Breast Arterial Calcification and Mortality and Cardiovascular Composite Outcome Stratified by Age Groups

321 Risk for mortality (**A-C**) and the cardiovascular composite outcome (**D-F**) by breast arterial calcification (BAC) presence/absence. Risk for both outcomes significantly varied by BAC status among women aged 40-59 years (**A, D**) and those aged 60-74 years (**B, E**) (p<0.001 for each);

322 however, among women aged 75-90 years (**C, F**), there was no significant difference in risk for either outcome by BAC status. The composite outcome included acute myocardial infarction, heart failure, stroke, and mortality. BAC indicates breast arterial calcification; BAC+, presence of BAC and BAC-, absence of BAC.

Figure 4. Association of Breast Arterial Calcification and Mortality and Cardiovascular Composite Stratified by Baseline Characteristics

Adjusted hazard ratios (HRs) for (**A**) mortality and **(B)** the cardiovascular composite outcome by breast arterial calcification (BAC) presence versus absence are presented. The composite outcome included acute myocardial infarction, heart failure, stroke, and mortality. BAC indicates breast arterial calcification; BAC+, presence of BAC and BAC-, absence of BAC. HRs presented were adjusted for age, race/ethnicity, systolic blood pressure, diastolic blood pressure, diabetes, total cholesterol, low-density lipoprotein cholesterol, smoking status, and history of cardiovascular disease, history of chronic kidney disease.

DISCUSSION

In this large, retrospective study, the presence and quantity of BAC were significantly associated with all-cause mortality and the CVD composite outcome, even after adjusting for established cardiovascular risk factors. The prevalence of BAC was 23%, which constitutes a substantial proportion of women (mean age of 56.8 years) undergoing routine screening mammography. To our knowledge, this is the first study to demonstrate a significant, independent relationship between a quantitative BAC score and all-cause mortality as well as a CVD composite outcome. For example, each 10-point increase as well as sequential quartiles of the Bradley score were both significantly associated with higher risk of mortality, highlighting the potential utility of BAC quantification for personalized risk assessment.

Prior studies have only evaluated the association of BAC using a binary or a semiquantitative approach (such as absence, slight, moderate, and severe intensity) with CVD outcomes [4,9]. In the present study, BAC was quantified using an automated method driven by a trained deep neural AI network, recently validated with high diagnostic performance.[8] Other machine learning techniques have been developed for BAC quantification, including a densitometry method, and have been validated prospectively.[10] Such studies have assessed methods of BAC quantification, though await association with clinical outcomes.[11-13] The findings in our study support the efficacy of assessing both BAC presence and quantitative BAC Bradley score to improve risk assessment for mortality and CVD outcomes in women undergoing screening mammography. With the advent of AI in medical imaging, automated, quantitative BAC assessment may facilitate seamless integration into clinical workflow and allow personalized risk assessment.

Importantly, this large study also demonstrated the association of BAC with CVD outcomes and mortality even among subgroups not already known to be "high risk", including younger women, non-smokers, and those without diabetes, high blood pressure, hyperlipidemia, CKD, or known CVD. We found that BAC was most predictive of future events among those in the youngest age group of 40-59 years, though BAC was also an independent predictor among women ages 60-74. Our results are concordant with those of Minssen et. al., who found that the diagnostic accuracy (~84%) for BAC with CAC was the highest in patients under the age of 60 years.[14] These findings are important, since they suggest that early risk-stratification with BAC in younger women may help identify new candidates for lifestyle modification and preventative therapies, and may ultimately help improve their outcomes. Indeed, results from this study and others suggest that BAC may develop at an earlier age than other traditional cardiovascular risk factors, and thus could serve as an early sign of underlying ASCVD risk.[15] Similarly, the independent association of BAC with outcomes even among women without various traditional comorbidities may provide opportunities to identify risk and prevent disease in a previously unrecognized subgroup of women.

Even with engagement from cardiologists and patients, the success of BAC implementation hinges on buy-in and education of the radiology community. A survey of the members of the Society of Breast Imaging found that 85% were aware of the association of BAC with CVD, but only 15% routinely included BAC data on mammogram reports.[16] One of the major barriers to universal BAC reporting is the lack of radiology society guidelines on reporting and appropriate use of BAC.[5,16] Automated quantification and reporting methods for BAC will be critical to ensure that the current radiology workflow is not compromised.[7] Therefore, it will be important

for cardiologists to advise and collaborate with the breast imaging community to develop clear

BAC reporting guidelines and apply automated quantification tools into clinical workflow.

If the development and implementation of BAC can follow a similar pathway as CAC, BAC may

someday be used to improve CVD risk stratification beyond current tools such as the Pooled

Cohort Equation (PCE), the ASCVD Risk Score, and the Framingham Risk Score (FRS).

Reclassification of risk will help identify those who will benefit from more aggressive lifestyle

modifications and medical therapy (i.e., statins, antihypertensives). Recently, the Multiethnic

Study of Breast Arterial Calcium Gradation and Cardiovascular Disease (MINERVA)

demonstrated that presence of BAC conferred additional risk at every category (i.e. low, medium

and high risk) of the PCE.[10] While our study did not include current CVD risk stratification tools,

we found that BAC was independently associated with mortality and various CVD outcomes.

Future studies should assess whether BAC could be used to help reclassify intermediate ASCVD

risk patients to guide initiation of statins, similar to CAC as suggested in the 2018 ACC/AHA

Cholesterol Guidelines.[17] Ultimately, BAC may offer important risk stratification information

without additional cost or radiation.[18]

Our study has a few limitations to note. First, the retrospective nature of the study does not prove

causality. Although attempts at reducing confounding using multivariable models were used,

residual risk remains. Clinical data including outcomes relied on the use of ICD-10 codes from

an EMR data extraction which introduces the possibility of misclassification. Also, mortality

information only included all-cause mortality; we did not have data on cause-specific mortality

including CVD death. Additionally, most subjects in this study identified as white, making

results most applicable to this population. Future research should focus on the implications of

BAC across more diverse populations to further support external validity of this potential

screening tool and to identify additional areas of opportunity.

CONCLUSION

In this large, retrospective study, both BAC presence and quantity are significantly and

independently associated with mortality and a CVD composite outcome. BAC appears to be

especially predictive of CVD risk among younger women. Reporting of BAC was feasible and

reliable using an automated AI algorithm, which could facilitate reporting uptake within the

radiology community. Further studies are needed to determine the appropriate clinical response

to BAC, and whether such a response can improve CVD outcomes in women.

ABBREVIATIONS

BAC (breast arterial calcification)

CVD (cardiovascular disease)

AI (artificial intelligence)

aHR (adjusted hazard ratios)

ASCVD (atherosclerotic cardiovascular disease)

FFDM (full-field digital mammograms)

MI (acute myocardial infarction)

HF (heart failure)

SBP (systolic blood pressure)

DBP (diastolic blood pressure)

LDL (low-density lipoprotein cholesterol)

CKD (chronic kidney disease)

EMR (electronic medical records)

UCSD (University of California, San Diego)

DISCLOSURES

Authors QMB, NN, ME, and LBD have served as consultants to CureMetrix. Authors RM and

JW are employees of CureMetrix. The first and senior authors had access to all data and drafted

the manuscript independently.

REFERENCES

1.   Chadashvili T, Litmanovich D, Hall F, Slanetz PJ. Do breast arterial calcifications on

mammography predict elevated risk of coronary artery disease? *Eur J Radiol.*

2016;85(6):1121-1124.

2.   McLenachan S, Camilleri F, Smith M, Newby DE, Williams MC. Breast arterial

calcification on mammography and risk of coronary artery disease: a SCOT-HEART sub-

study. *Clin Radiol.* 2019;74(6):421-428.

3.   Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease

Commission: reducing the global burden by 2030. *The Lancet.* 2021;397(10292):2385-

2438.

4.   Bui QM, Daniels LB. A Review of the Role of Breast Arterial Calcification for

Cardiovascular Risk Stratification in Women. *Circulation.* 2019;139(8):1094-1101.

5.   Margolies LR, Yip R, Hwang E, et al. Breast Arterial Calcification in the Mammogram

Report: The Patient Perspective. *AJR Am J Roentgenol.* 2019;212(1):209-214.

6.   Iribarren C, Molloi S. Breast Arterial Calcification: a New Marker of Cardiovascular

Risk? *Curr Cardiovasc Risk Rep.* 2013;7(2):126-135.

7.   Yoon YE, Yun B, Kim KM, Suh JW. Breast Arterial Calcification: A Potential

Biomarker for Atherosclerotic Cardiovascular Disease Risk? *Curr Atheroscler Rep.*

2021;23(5):21.

8.   Goel V CW, Spear E, Sultana N, Chan J, Chee Cheen Y, Tan S, Tan C, Mantey R, Brown

A, Nerlekar N. Artificial Intelligence Software Demonstrates High Performance for

Breast Arterial Calcification Detection on Mammography. *Heart, Lung, and Circulation.*

2023;32:S383.

9.   Oliveira EL, Freitas-Junior R, Afiune-Neto A, Murta EF, Ferro JE, Melo AF. Vascular

calcifications seen on mammography: an independent factor indicating coronary artery

disease. *Clinics (Sao Paulo).* 2009;64(8):763-767.

10.   Iribarren C, Chandra M, Lee C, et al. Breast Arterial Calcification: a Novel

Cardiovascular Risk Enhancer Among Postmenopausal Women. *Circ Cardiovasc*

Imaging. 2022;15(3):e013526.

11.   Khan R MG. Detecting Breast Arterial Calcifications in Mammograms with Transfer

Learning. *Electronics.* 2023;12(1):231.

12.   Molloi S, Xu T, Ducote J, Iribarren C. Quantification of breast arterial calcification using

full field digital mammography. *Med Phys.* 2008;35(4):1428-1439.

13.   Guo X, O'Neill WC, Vey B, et al. SCU-Net: A deep learning method for segmentation

and quantification of breast arterial calcifications on mammograms. *Med Phys.*

2021;48(10):5851-5861.

14.   Minssen L, Dao TH, Quang AV, et al. Breast arterial calcifications on mammography: a

new marker of cardiovascular risk in asymptomatic middle age women? *Eur Radiol.*

2022.

15.   Allen TS BQ, Sykes AV, Belrose N, Nerlekar N, Mantey R, Wang J, Eghtedari M,

Daniels LB. Abstract 11669: Quantitative and Automated Breast Arterial Calcification

Score is Associated With Traditional Cardiovascular Risk Factors. *Circulation.* 2022;146.

16.   Collado-Mesa F YM, Arheart K. Breast Arterial Calcifications on Mammography: A

Survey of Practicing Radiologists. *Journal of Breast Imaging.* 2021;3:438-447.

17.   Grundy SM, Stone NJ, Bailey AL, et al. 2018

AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA

Guideline on the Management of Blood Cholesterol: A Report of the American College

of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Circulation. 2019;139(25):e1082-e1143.

18.   Statistics NCfH. Health, United States, 2016: With Chartbook on Long-term Trends in

Health. In. Hyattsville, MD2017.